Cargando…
PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives
(68)Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative intended therapy. Owed to the novelty of the PSMA-targeting tracers, clinical evidence o...
Autores principales: | Zschaeck, Sebastian, Lohaus, Fabian, Beck, Marcus, Habl, Gregor, Kroeze, Stephanie, Zamboglou, Constantinos, Koerber, Stefan Alexander, Debus, Jürgen, Hölscher, Tobias, Wust, Peter, Ganswindt, Ute, Baur, Alexander D. J., Zöphel, Klaus, Cihoric, Nikola, Guckenberger, Matthias, Combs, Stephanie E., Grosu, Anca Ligia, Ghadjar, Pirus, Belka, Claus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5948793/ https://www.ncbi.nlm.nih.gov/pubmed/29751842 http://dx.doi.org/10.1186/s13014-018-1047-5 |
Ejemplares similares
-
Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database
por: Cihoric, Nikola, et al.
Publicado: (2018) -
Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients
por: Zschaeck, Sebastian, et al.
Publicado: (2017) -
Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021) -
Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2023) -
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)